ArticleMolecular imaging and biology2012
Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model.
Article in Molecular imaging and biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements.European journal of nuclear medicine and molecular imaging · 2015Trial
- First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Trial
- A comparison study of dynamic [Journal of cancer research and clinical oncology · 2024Article
- TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.International journal of molecular sciences · 2022Article
- The Feasibility of Targeted Magnetic Iron Oxide Nanoagent for Noninvasive IgA Nephropathy Diagnosis.Frontiers in bioengineering and biotechnology · 2021Article
- Article
- (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.European journal of nuclear medicine and molecular imaging · 2016Article
- Article
- MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.PloS one · 2016Article
- Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3.Theranostics · 2016Review
- (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases.European journal of nuclear medicine and molecular imaging · 2015Article
- Evaluation of Tc-99 m Labeled Dimeric GX1 Peptides for Imaging of Colorectal Cancer Vasculature.Molecular imaging and biology · 2015Article
- Radiolabeled RGD tracer kinetics annotates differential αvβ 3 integrin expression linked to cell intrinsic and vessel expression.Molecular imaging and biology · 2014Article
- PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments.BioMed research international · 2014Review
- (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Article
- Nanotheranostics for personalized medicine.Expert review of molecular diagnostics · 2013Review
- Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe.Theranostics · 2012Article
- Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeNon-invasive PET imaging with radiolabeled RGD peptides for α(v)β(3) integrin targeting has become an important tool for tumor diagnosis and treatment monitoring in both pre-clinical and clinical studies. To better understand the molecular process and tracer pharmacokinetics, we introduced kinetic modeling in the investigation of (18)F-labeled RGD peptide monomer (18)F-FP-c(RGDyK) (denoted as (18)F-FPRGD) and dimer (18)F-FP-PEG3-E[c(RGDyK)](2) (denoted as (18)F-FPPRGD2). PROCEDURES: MDA-MB-435 tumor-bearing mice underwent 60 min dynamic PET scans following the injection of either (18)F-FPRGD or (18)F-FPPRGD2. Blocking studies with pre-injection of a blocking mass dose were performed for both monomeric and dimeric RGD groups. (18)F-FPRAD (RAD) was used as a negative control. Kinetic parameters (K(1), k(2), k(3), k(4)) of a three-compartment model were fitted to the dynamic data to allow quantitative comparisons between the monomeric and dimeric RGD peptides.
resultsDimeric RGD peptide tracer showed significantly higher binding potential (Bp(ND) = k(3)/k(4), 5.87 ± 0.31) than that of the monomeric analog (2.75 ± 0.48, p = 0.0022, n = 4/group). The Bp(ND) values showed a significantly greater ratio (dimer/monomer ~2.1) than the difference in %ID/g uptake measured from static images (dimer/monomer ~1.5, p = 0.0045). Significant decrease in Bp(ND) was found in the blocked groups compared with the unblocked ones (dimer p = 0.00024, monomer p = 0.005, n = 4/group). Similarly, the RAD control group showed the lowest Bp(ND) value among all the test groups, as the RAD peptide does not bind to integrin α(v)β(3). Volume of distribution (V(T) = K(1)/k (2)(1 + k (3)/k (4))) could be separated into non-specific (V (ND) = K (1)/k (2)) and specific (V (S) = K (1) k (3)/(k (2) k (4))) components. Specific distribution volume (V(S)) was the dominant component of V(T) in the unblocked groups and decreased in the blocked groups. Unblocked RGD dimer also showed higher V(S) than that of the monomer (dimer V(S) = 2.38 ± 0.15, monomer V(S) = 0.90 ± 0.17, p = 0.0013, n = 4/group), well correlated with Bp(ND) calculations. Little difference in V(ND) was found among all groups. Moreover, parametric maps allowed quantitative analysis at voxel level and provided higher tumor-to-background contrast for Bp(ND) maps than the static images. Tumor heterogeneity in kinetic parameters was found in parametric images, which could not be clearly identified in static intensity images.
conclusionsThe pharmacokinetics of both monomeric and dimeric RGD peptide tracers was compared, and the RGD dimers showed significantly higher binding affinity than the monomeric analogs. Kinetic parameters were demonstrated to be valuable for separating specific and non-specific binding and may allow more sensitive and detailed quantification than simple standardized uptake value analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.